ResMed is a medical instruments & supplies business based in Australia. ResMed shares (RMD) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. ResMed has a trailing 12-month revenue of around $4.7 billion. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as ResMed, you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose or you can see our list of the best share trading platforms in Australia. Then follow these steps.
Our top pick for
Best for day trading
Our top pick for
Education & learning
Our top pick for
Low commission
| 52-week range | $20.6929 - $35.97 |
|---|---|
| 50-day moving average | $31.386 |
| 200-day moving average | $29.3347 |
| Target price | $35.09 |
| PE ratio | 35.0196 |
| Dividend yield | $1.92 (8.99%) |
| Earnings per share (TTM) | $1.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$36.21
| 1 week (2024-08-29) | 1.71% |
|---|---|
| 1 month (2024-08-05) | 10.63% |
| 3 months (2024-06-05) | 13.87% |
| 6 months (2024-03-05) | 30.20% |
| 1 year (2023-09-05) | 47.68% |
|---|---|
| 2 years (2022-09-05) | 14.19% |
| 3 years (2021-09-03) | -7.86% |
| 5 years (2019-09-05) | 77.07% |
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, ResMed shares trade at around 35x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0315. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 billion (£0.0 million).
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $4.7 billion |
|---|---|
| Operating margin TTM | 31.17% |
| Gross profit TTM | $2.4 billion |
| Return on assets TTM | 12.7% |
| Return on equity TTM | 22.7% |
| Profit margin | 21.79% |
| Book value | 33.111 |
| Market capitalisation | $52.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 78.37% of net profits
Recently ResMed has paid out, on average, around 78.37% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 8.99% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 8.99% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about A$1.92 per share.
ResMed's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 13 August 2024 (the "ex-dividend date").
ResMed's shares were split on a 2:1 basis on 11 August 2010. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
Over the last 12 months, ResMed's shares have ranged in value from as little as $20.6929 up to $35.97. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while ResMed's is 0.664. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
We used Finder's proprietary algorithm to find the 10 best stocks under $10 on the ASX.
We used Finder's proprietary algorithm to find Australian-listed companies that have strong fundamentals and have a share price under $5.
Here are our algorithm-selected 20 Aussie stocks worth watching in 2024.
Find out the different ways you can invest in the S&P 500 index from Australia.
Following a couple of lean years for dividend investors, here are 20 ideas you could consider in your portfolio.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
A beginner's guide to options trading in Australia. Read the step-by-step process and compare brokers to start trading.
If you're looking to start your investment journey, here's how to open a share trading account.
Compare share trading apps to find out which app has all the tools and resources you need to reach your investment goals.
Follow these tips to find the best share trading platform for you.